Inactivation of the SMARCA4 gene, which encodes BRG1 protein, increases tumor invasiveness and affects sensitivity to conventional platinum-based chemotherapeutic agents but may increase tumor sensitivity to EZH2 inhibitors, CDK4/6 inhibitors (3). This evidence concerns the gene SMARCA4 and neoplasm.